🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and arterial inflammation — March 2026 Page 6

GLP-1 and arterial inflammation — March 2026

laura_annarbor Tue, Dec 16, 2025 at 3:06 AM 28 replies 1,163 viewsPage 6 of 6
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Dec 21, 2025 at 7:04 AM#26

One thing that is still open after KevinCompounds’s answer:

What did you change at the same time, and can you separate the two now?

22 22DoseLogDan, SleepFixSam, PurityPaulOR and 19 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Dec 21, 2025 at 1:24 PM#27
SleepDoc_PDX said:
KevinCompounds said: ...we're creating a generation dependent on cardiovascular risk...
SleepDoc_PDX said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

Last edited: Dec 21, 2025 at 5:24 PM
21 21newstart_MO, mia_MS2, LeilaHI and 18 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Dec 21, 2025 at 7:44 PM#28
SleepDoc_PDX said:
KevinCompounds said: ...we're creating a generation dependent on cardiovascular risk...

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

16 months later: down 63 lbs, off metoprolol, A1C from 8.6% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

20 20PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 17 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Dec 22, 2025 at 2:04 AM#29
SleepDoc_PDX said:
KevinCompounds said: ...we're creating a generation dependent on cardiovascular risk...

Thank you — that is the clearest version of this I have read, and I have read a lot of them. I will report back once I have actually tried it.

19 19Dr.MetabolicMD, RetaRick_CA, JenPlateau and 16 others
Reply Quote Save Share Report
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
Dec 22, 2025 at 8:24 AM#30
NurseLeah_Nash said:
I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

6 month update on cardiovascular risk: down 47 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

47 22JenMemphis, pat_auckland, Dr.GastroMayo and 44 others
Reply Quote Save Share Report
1456

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register